Fresenius Kabi Makes Progress On Tocilizumab
Reports Positive Phase I Results For Actemra/Ro-Actemra Biosimilar
Executive Summary
Fresenius Kabi has reported positive Phase I data for its MSB11456 proposed tocilizumab biosimilar rival to Actemra/Ro-Actemra, against the backdrop of shortages for the brand which is being used in some regions to treat COVID-19.
You may also be interested in...
FDA Accepts Kabi’s Actemra Biosimilar – Will It Be First?
Fresenius Kabi has been tipped to strike first in the race to launch a biosimilar to Actemra – a market where competition “is likely to be thin for some time.”
Kabi Brings In Reddy’s Rituximab As Biosimilar Breakeven Date Retreats
The Fresenius group had much to say of Fresenius Kabi’s biosimilar business during the firm’s Q4 and year-end results call, which disclosed a US in-licensing deal for Dr Reddy’s proposed rituximab biosimilar and suggested additional biosimilar manufacturing is among its top priorities.
Fresenius Kabi Concedes On FDA Pegfilgrastim Chances
Fresenius Kabi is continuing to suffer from the longstanding effects of the US FDA backlog for onsite inspection reviews amid the coronavirus pandemic. Management discussed Kabi’s latest prospects on its proposed pegfilgrastim biosimilar, as well as adalimumab and tocilizumab.